1/1 - (C) WPI / DERWENT
AN - 83-767184 ç25!
AP - JP820015574 820204
PR - JP820015574 820204
TI - Anticancer drug - comprising ribosome modified with mono-clonal antibody
IW - ANTICANCER DRUG COMPRISE RIBOSOME MODIFIED MONO CLONE ANTIBODY
PA - (HASH-I) HASHIMOTO Y
PN - JP58134032 A 830810 DW8338 003pp
- JP3055450B B 910823 DW9138 000pp
ORD - 1983-08-10
IC - A61K9/10 ; A61K31/71 ; A61K37/02 ; A61K39/44
FS - CPI
DC - B04
AB - J58134032 A ribosome modified with a monoclonal antibody forms an anticancer material in particle and/or membrane form. The ribosome exerts specifically for cancer tissue and the anticancer material is transferred into cancer cells. Therefore, the anticancer drug containing the ribosome has little in the way of side effects.
- The anticancer material is mixed into a soln. of the constituent lipid of the ribosome and a monolayer ribosome is formed by ultrasonic treatment etc. in a conventional manner. Thereby, fat-soluble anticancer material is uniformly dispersed into a membrane and water-soluble anticancer material is enclosed in lipid vesicle, and therefore the ribosome is present in the form if microcapsule. To introduce the monoclonal antibody into the membrane, an antibody fragment carrying SH-gps. is used. For IgM, IgM antibody is treated with e.g. cysteine to reduce only J-chain and IgM subunit (IgMs) having two mercapto gps. is prepd. Ribosome having many maleimide gps. originating from m-maleimidebenzoyl -N-(dipalmitoylphosphatidyl) ethanolamine on its membrane is used. IgMs is added to the soln. of the ribosome in PBS and incubated at 37 deg.C for about 1 hr. to cause SH-addn. reaction.